ライフサイエンスコーパス: gadodiamide

1 sed to gadobenate dimeglumine in addition to gadodiamide.

2 patients in the contrast group had received gadodiamide.

3 with 3D MR DSA after the bolus injection of gadodiamide.

4 ed to transendocardially inject a mixture of gadodiamide (0.05 mol/L) plus Evans blue dye (3%).

5 A high concentration of gadodiamide (0.5 mol/L) was used to demarcate the border

6 In vitro, the attenuation of undiluted gadodiamide (3,069 HU) was equivalent to that of ioverso

7 ll 13 rats underwent 11.75-T MR imaging with gadodiamide (60 muL) 13 days after tumor implantation.

8 In the cerebellum, the amount of intact gadodiamide accounts for 18.2% +/- 10.6 of the total gad

9 amide dose, renal function, and time between gadodiamide administration and phlebotomy.

10 Gadodiamide administration causes spurious hypocalcemia,

11 nges in serum calcium measurements following gadodiamide administration in 1,049 MR imaging examinati

12 inium retention in skin following formulated gadodiamide administration was located to the collagen f

13 calcium measurements up to 4(1/2) days after gadodiamide administration.

14 iron, as opposed to those animals exposed to gadodiamide alone; this experiment suggests that great c

15 The mean fDV of both tracers (gadodiamide and (99m)Tc-DTPA) in normal myocardium was 1

16 ed 48 hours after bevacizumab treatment with gadodiamide and 72 hours after treatment with ferumoxyto

17 Rats treated with gadodiamide and both Epo and intravenous iron (group D)

18 r-Wistar rats: group A, gadodiamide only; B, gadodiamide and Epo; C, gadodiamide and intravenous iron

19 ollowing administration of the linear agents gadodiamide and gadobenate dimeglumine compared with the

20 Relaxometric measurements of gadodiamide and gadolinium trichloride in the presence o

21 the gadolinium-based contrast agents (GBCAs) gadodiamide and gadoteridol and to quantify the amount o

22 The mean total gadolinium concentrations for gadodiamide and gadoteridol, respectively, were 0.317 mu

23 gadodiamide only; B, gadodiamide and Epo; C, gadodiamide and intravenous iron; and D, gadodiamide, Ep

24 uation measurements of multiple dilutions of gadodiamide and ioversol were compared.

25 agnosis, all 13 patients had been exposed to gadodiamide and one had been exposed to gadobenate dimeg

26 r group) included low-dosage and high-dosage gadodiamide and osmolality-matched saline controls.

27 DSC MR imaging with gadodiamide and without preload showed low rCBV (</= 1.7

28 underwent DCE MR imaging after injection of gadodiamide, and gadolinium concentration-time curves we

29 by gadoversetamide, gadobenate dimeglumine, gadodiamide, and gadopentetate dimeglumine at a concentr

30 Gadodiamide appears to be a safe and useful intraarteria

31 th air as the contrast material) or T1 (with gadodiamide as the contrast material).

32 Eleven mice received gadodiamide before XFM.

33 Delivery of the gadodiamide-blue dye mixture and the consequences of the

34 to visualize the myocardial delivery of the gadodiamide-blue dye mixture.

35 Injection of gadodiamide caused a significant (P <.05) decrease in th

36 Gadoversetamide and gadodiamide caused a transient artifact in measurement o

37 A high concentration of gadodiamide caused signal intensity loss around the gado

38 Findings were correlated with first-pass gadodiamide contrast magnetic resonance imaging (MRI) in

39 Intravenous gadodiamide contrast was administered to define EOM tend

40 ulleys were directly imaged with intravenous gadodiamide contrast.

41 s after dosing with up to 20 repeat doses of gadodiamide (cumulative dose, 12 mmol per kilogram of bo

42 serum creatinine level (r = 0.39, P <.001), gadodiamide dose (r = 0.37, P <.001), and time between g

43 ormed in these patients were correlated with gadodiamide dose, renal function, and time between gadod

44 in association with gadolinium exposure (eg, gadodiamide) either in the sclerotic skin in NSF or in G

45 Gadodiamide-enhanced angiograms appeared to be better th

46 Gadodiamide-enhanced angiograms were compared with CO2-e

47 Following 42 gadodiamide-enhanced examinations, serum calcium measure

48 f NSF was one in 2913 patients who underwent gadodiamide-enhanced MR examinations and one in 44,224 p

49 serum calcium data obtained before and after gadodiamide-enhanced MR imaging were identified.

50 ups: Group 1 included patients who underwent gadodiamide-enhanced MR imaging, and group 2 included pa

51 GP:TH and DN:MCP is associated with multiple gadodiamide-enhanced studies but not with gadobenate dim

52 een obtained with a 1.5-T MR unit by using a gadodiamide-enhanced T1-weighted spoiled gradient-recall

53 anges were more marked in animals exposed to gadodiamide, Epo, and intravenous iron, as opposed to th

54 C, gadodiamide and intravenous iron; and D, gadodiamide, Epo, and intravenous iron.

55 ssues from the four neuroanatomic regions of gadodiamide-exposed patients contained 0.1-19.4 mug of g

56 ses of gadoversetamide; 1.0-mmol/kg doses of gadodiamide, gadopentetate, and gadoteridol; and a 6-mL/

57 The linear gadolinium contrast agents (gadodiamide, gadoversetamide, gadopentetate dimeglumine,

58 y the soluble paramagnetic relaxation agent, gadodiamide (Gd(DTPA-BMA)).

59 The nonionic linear chelate gadodiamide had the lowest rate of reactions, at 1.5 (95

60 events with use of the nonionic linear GBCA gadodiamide in comparison with those of ionic linear or

61 diffusion rates for Gd(3)N@C(80) relative to gadodiamide in live normal rat brain tissue.

62 13 mmol/L of Gd(3)N@C(80) and 0.50 mmol/L of gadodiamide in live normal rat brain.

63 Formulated gadodiamide increased dermal cell count, dermal thicknes

64 Omniscan and gadodiamide induced strong TLR4- and TLR7-mediated repor

65 ium per gram of tissue (95% CI: 6.2, 7.0) in gadodiamide-injected rats; a significant positive dose-s

66 The fDVs of gadodiamide injection and (99m)Tc-DTPA were measured and

67 e dose (r = 0.37, P <.001), and time between gadodiamide injection and phlebotomy (r = -0.28, P <.001

68 ows were injected with a solution containing gadodiamide, iodinated contrast agent, and gelatin.

69 intravenous administration of 0.2 mmol/kg of gadodiamide, MDE-MRI was obtained.

70 Gadolinium-based contrast agents, formulated gadodiamide (n = 9) and gadoterate meglumine (n = 11), w

71 = .004) compared with the rate treated with gadodiamide only (group A).

72 our groups of Hannover-Wistar rats: group A, gadodiamide only; B, gadodiamide and Epo; C, gadodiamide

73 urements after administration of 0.1 mmol of gadodiamide per kilogram of body weight were greater in

74 administration was dependent on the dose of gadodiamide preload, whereas the magnitude of rCBV decre

75 Formulated gadodiamide produced a 40-fold greater increase in gadol

76 higher than that for commercial agents (eg, gadodiamide); r1 values of 102, 143, and 32 L . mmol(-1)

77 Use of high-risk GBCAs, such as formulated gadodiamide, should be avoided in patients with renal di

78 Gadodiamide showed a significant increase in DN:MCP and

79 Omniscan and gadodiamide signaling via TLRs 4 and 7 resulted in incre

80 r administration of more than 0.2 mmol/kg of gadodiamide, spurious calcium measurement decreases were

81 fore and after intravenous administration of gadodiamide), the pigs were observed for 7 days and foll

82 ared with reference Gd2O3 and contrast agent Gadodiamide, the features in the RIXS spectra of all met

83 In rats treated with gadodiamide, the largest part of gadolinium retained in

84 Following the switch from gadodiamide to gadobenate dimeglumine and gadopentetate

85 otein associations that impede the access of gadodiamide to the residues of the interaction surface.

86 renal interventions were performed by using gadodiamide (total dose, 0.3 mmol/kg) and CO2 as intraar

87 hough it is considerably less than that with gadodiamide use.

88 related to a particular type of gadolinium (gadodiamide) used for contrast-enhanced radiologic studi

89 High-dose gadodiamide was administered, 2.5 mmol per kilogram of b

90 Gadodiamide was the only agent used in the preadoption p

91 Gadodiamide was used at University of North Carolina at

92 SF was much greater at the two centers where gadodiamide was used than at the two centers where gadop

93 In three pigs, 50-mL boluses of undiluted gadodiamide were injected intravenously at 2 mL/sec, and

94 resent in the brain after repeat dosing with gadodiamide, which is partially cleared over 20 weeks wi

95 ed gadolinium was intact soluble GBCA, while gadodiamide yielded both soluble and insoluble gadoliniu